Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
The patient, diagnosed with chylomicronemia, had a long history of fasting triglyceride (TG) levels exceeding 12.5 mmol/L and recurrent acute pancreatitis. In the dose-escalation IIT for CS-121, his fasting TG level dropped significantly within three days after a single low-dose administration, with no adverse events. The patient, diagnosed with chylomicronemia, had a long history of fasting triglyceride (TG) levels exceeding 12.5 mmol/L and recurrent acute pancreatitis. In the…
PR Newswire
06/11/2025
Rheumatoid Arthritis Market to Surge by 2034 as Next-Generation Biologics and…
Rheumatoid Arthritis Market Summary Rheumatoid Arthritis Market Summary Discover the rheumatoid arthritis new treatment @New Treatments for Rheumatoid Arthritis Key Factors Driving the Growth of the Rheumatoid Arthritis Market Rising Rheumatoid Arthritis Disease Prevalence According to DelveInsight's estimates, the US accounted for around~1.3 milliondiagnosed prevalent cases of rheumatoid arthritis in 2024. These cases are further expected to increase by 2034...
PR Newswire
05/11/2025
Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved…
Unlike many other diseases, there are no set guidelines on treatment targets for obesity, and outcomes often rely on percentage weight loss onlyBody mass index (BMI) and waist-to-height ratio (a measurement of unhealthy waist size) represent important obesity treatment targets, associated with a lower risk of obesity-related complicationsA study of people with obesity (STEP UP trial) showed that more people taking Wegovy ®achieved a BMI under 27 and a waist-to-height ratio of less than 0...
Nasdaq GlobeNewswire
05/11/2025
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates…
– 3Q25 total revenues increased 7% year-over-year driven by robust growth of Epidiolex®, Xywav® and the launch of Modeyso – – 3Q25 total revenues increased 7% year-over-year driven by robust growth of Epidiolex® , Xywav® and the launch ofModeyso– DUBLIN , Nov. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2025 and updated financial guidance for 2025. "Achieving the highest revenue quarter in...
PR Newswire
05/11/2025
Galapagos Reports Nine Months 2025 Financial Results and Provides Business…
Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of leadership team aligned with strategic direction Robust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025 cash position expected at €2.975 billion to €3.025 billion Management to host a ...
Nasdaq GlobeNewswire
05/11/2025
Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare…
Media ReleaseCOPENHAGEN, Denmark; November 5, 2025 Genmab A/S (Nasdaq:GMAB)announced today that its Chief Executive Officer Jan Van de Winkel and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Jefferies Global Healthcare Conference in London at 12:00 PM GMT(7:00AM EST)on November 19 , 2025 . A webcast of the fireside chat will be available on Genmab’s website athttps://ir.genmab...
Nasdaq GlobeNewswire
05/11/2025
VALNEVA Declaration of shares and voting rights: October 31, 2025
VALNEVADeclaration of shares and voting rightsOctober 31, 2025__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: November 5, 2025 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights* Description of the...
Nasdaq GlobeNewswire
05/11/2025
Holistic Luxury Meets Heritage: India's Swastik Wellbeing unveils its Ancient…
The Swastik leadership team believes that India has always been the cradle of healing and conscious living. "The global traveller today seeks wellbeing across five dimensions of Health, Wealth, Love, Bliss and Spirituality. Swastik represents India's evolution as a conscious luxury destination, where wellbeing is lived, felt and culturally rooted," said Ms. Anushree Nyati, Director, Swastik Wellbeing. The Swastik leadership team believes thatIndiahas always been the cradle of healing…
PR Newswire
05/11/2025
Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific…
New analysis confirms reductions in blood pressure and albuminuria by aprocitentan in patients with true resistant hypertension and high cardiovascular risk – including chronic kidney diseaseAllschwil, Switzerland – November 05, 2025Idorsia Ltd (SIX: IDIA) shares that new analysis of the landmark Phase 3 PRECISION study of aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented at theAmerican Society of Nephrology (ASN) Kidney Week 2025, taking place in Houston,...
Nasdaq GlobeNewswire
05/11/2025
Sobi to present New One-Year Data on pegcetacoplan's efficacy in C3G and primary…
"Patients on Aspaveli/Empaveli maintained proteinuria reduction, irrespective of taking immunosuppressants and independent of their baseline proteinuria levels. One third of patients achieved complete proteinuria remission compared to 3% for placebo at week 26. These benefits were maintained through one year, and patients who switched from placebo experienced similar improvements. This demonstrates the potential of Aspaveli/Empaveli to transform care for people living with these rare…
PR Newswire
05/11/2025
Hyaluronic Acid Products Market to Reach $20 billion, Globally, by 2034 at 7.7%…
Market Introduction Market Introduction The hyaluronic acid (HA) products market involves a broad range of therapeutic and aesthetic applications derived from hyaluronic acid, a naturally occurring polysaccharide known for its hydration and tissue-repair properties. HA products include dermal fillers, osteoarthritis injections, ophthalmic solutions, wound care formulations, nasal sprays, and drug delivery systems. The market has gained significant momentum due to increasing demand for...
PR Newswire
05/11/2025
Ophthalmic Equipment Market worth US$26.14 billion by 2030 with 5.9% CAGR |…
Browse in-depth TOC on "Ophthalmic Equipment Market" Browse in-depth TOC on "Ophthalmic Equipment Market" 350 - Tables50 - Figures400 - Pages By technology,non-AI-enabled equipment holds the largest market share in the ophthalmic equipment market because of its widespread availability, lower cost, and established clinical reliability. These systems are widely used across hospitals and clinics, requiring minimal technical expertise and maintenance. Additionally, slower...
PR Newswire
05/11/2025
Diaper Rash Cream Market to Reach $4.0 Billion, Globally, by 2033 at 5.8% CAGR…
Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A10633 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A10633 Prime determinants of growth The global diaper rash cream market is experiencing growth due to several factors such as increasing awareness of skin health in infants and adults and advancements in product formulations and organic options. However, high product costs and...
PR Newswire
05/11/2025
Andor Health's Agentic AI Platform, ThinkAndor®, Receives Frost & Sullivan's…
Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: transformational innovation and customer impact. Andor Health excels in both, demonstrating its ability to align strategic initiatives with market demand and execute them efficiently, consistently, and at scale. Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: transformational innovation and customer impact. Andor Health excels…
PR Newswire
05/11/2025
Santen Receives UK Approval for Ryjunea® (low-dose atropine 0.1 mg/ml) to Slow…
The first signs of myopia often appear in daily life: a child squinting to read the board, moving closer to the TV, or struggling to recognise faces at a distance.[6] Myopia can affect learning, confidence, and participation in school and play.[9] Early interventions are key to slowing progression and supporting children's eye health and wellbeing.[10] The first signs of myopia often appear in daily life: a child squinting to read the board, moving closer to the TV, or struggling to recognise...
PR Newswire
05/11/2025
Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a…
A cardiometabolic post hoc analysis from the OASIS 4 phase 3 clinical trial examined how the amount of weight patients lost affects glycemic parameters (blood sugar control) and cardiovascular (CV) risk factors in adults with overweight and obesity. In participants with overweight or obesity, once-daily oral semaglutide 25 mg treatment compared with placebo led to greater improvements in glycemic parameters, including HbA1c, fasting plasma glucose, and fasting serum insulin, as well as CV risk…
PR Newswire
05/11/2025
MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten…
ZUG, Switzerland, November 5, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on advancing therapies to address significant unmet needs in inflammatory skin and joint diseases, today announced the pricing of an underwritten offering of 7,142,857 Class A ordinary shares at an offering price per share of $10.50. The gross proceeds from the offering to MoonLake, before deducting the underwriting discounts and commissions and other...
Nasdaq GlobeNewswire
05/11/2025
MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and…
Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to provide runway into the second half of 2027Reported results of its Phase 2 LEDA clinical trial in Palmoplantar Pustulosis (PPP) where sonelokimab (SLK) demonstrated clinically meaningful and statistically significant benefitReported an interim analysis of the long-term data from the VELA-1...
Nasdaq GlobeNewswire
05/11/2025
NCH Becomes First U.S. Hospital to Use AI That Detects Hidden Heart Attack Risk…
Caristo's FDA-cleared CaRi-Plaque™ technology analyzes coronary CT angiography (CCTA) scans, the first-line test for patients with chest pain, to identify high-risk plaque that may lead to future heart attacks. CaRi-Heart™ is the only technology in the world able to detect and quantify coronary inflammation, an early driver of heart disease, without waiting for patients to develop visible plaque. Caristo's FDA-clearedCaRi-Plaque™technology analyzes coronary CT angiography (CCTA) scans, the...
PR Newswire
05/11/2025
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of…
ORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in initial cohorts of ongoing Phase 2a study; Data mark first robust demonstration of oral OX2R agonist addressing wakefulness needs of patients across all three indications; Expect to initiate registrational program in Q1 2026ORX142: Phase 1 data support highly differentiated profile; Expect to initiate patient studies in Q1 2026 ...
Nasdaq GlobeNewswire
05/11/2025
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3…
For an accessible version of this Press Release, please visit www.tevapharm.com Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Excluding Japan BV in Q3 2024, revenues increased 5% in U.S. dollars or 3% in LC. United States segment increased by 12%; Europe segment decreased by 10% in LC; and International Markets segment decreased by 10% in LC, or increased by 2% in LC excluding Japan BV...
Nasdaq GlobeNewswire
05/11/2025
Private Placement of Financière de Tubize shares
Financière de Tubize has been informed that a block of 882k existing ordinary shares (1,98% of Financière de Tubize capital) has been offered yesterday, after Euronext Brussels market close, within the framework of a private placement (Accelerated Bookbuild). This is the result of the donation of a non-family shareholder to some not-for-profit organisations who mandated Bank Degroof Petercam to sell their shares.
Nasdaq GlobeNewswire
05/11/2025
AMP 2025: DNAe to unveil latest data from world's first NGS-based, fully…
Samuel Reed, CEO of DNAe, commented: "We're heading to AMP at a hugely exciting phase in the delivery of our LiDia-SEQ™ diagnostic platform, with news of our latest datasets already generating strong interest across the molecular diagnostics community. Our focus now is on completing the development of our flagship BSI/AMR test on the LiDia-SEQ™ platform – a highly sensitive, fully automated test from whole blood samples that will enable rapid detection and identification of life-threatening…
PR Newswire
05/11/2025
Companion Diagnostics Market Worth USD 15.6 Bn by 2030 Growing at 12.4% CAGR…
North America continues to dominate the companion diagnostics market, supported by a robust pharmaceutical pipeline, favorable reimbursement policies, and early adoption of molecular testing technologies. The region's regulatory clarity from the FDA for co-development of drugs and diagnostics has also streamlined commercialization pathways. North America continues to dominate the companion diagnostics market, supported by a robust pharmaceutical pipeline, favorable reimbursement policies,...
PR Newswire
05/11/2025
Altri Comunicati
